Welcome to our dedicated page for Orchestra BioMed Holdings Ordinary Shares news (Ticker: OBIO), a resource for investors and traders seeking the latest updates and insights on Orchestra BioMed Holdings Ordinary Shares stock.
Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) is a biomedical innovation company dedicated to bringing high-impact technologies to patients through strategic partnerships. The company's unique business model relies on risk-reward sharing collaborations with leading medical device companies, facilitating global commercialization of its innovative products.
Core Offerings and Innovations
- BackBeat Cardiac Neuromodulation Therapy (CNT): This flagship product targets hypertension, an extensive global health issue. BackBeat CNT uses atrioventricular interval modulation (AVIM) therapy administered through standard dual-chamber pacemakers to significantly and persistently reduce blood pressure.
- Virtue Sirolimus AngioInfusion Balloon (SAB): This product is aimed at treating atherosclerotic artery disease, the leading cause of mortality worldwide. The Virtue SAB is a novel drug-delivery system designed to address the specific needs of patients with this condition.
Recent Achievements
In January 2024, Orchestra BioMed announced the successful randomization of the first patient in the BACKBEAT pivotal study, aimed at assessing the efficacy and safety of AVIM therapy in pacemaker-indicated patients with uncontrolled hypertension. This study is crucial for determining the effectiveness of the BackBeat CNT in reducing blood pressure.
Strategic Partnerships
Orchestra BioMed has formed pivotal partnerships to drive its mission. In July 2022, the company entered a strategic collaboration with Medtronic for the commercialization of AVIM therapy. This partnership will enable Medtronic to exclusively commercialize AVIM-enabled pacing systems globally, with Orchestra BioMed sharing in the resultant revenues. Additionally, a strategic partnership with Terumo focuses on the development and commercialization of Virtue SAB.
Financial Condition and Market Presence
Orchestra BioMed is financially robust and strategically positioned in the biomedical sector, with a clear focus on growing its product pipeline through acquisitions, strategic collaborations, and organic development. This approach ensures sustained innovation and market relevance.
For more detailed information, visit www.orchestrabiomed.com and follow the company on LinkedIn and X (formerly Twitter).
Vivasure Medical announced its pivotal PATCH Clinical Study for the PerQseal® Closure Device has received FDA Investigational Device Exemption (IDE) approval. The study will enroll up to 188 patients in the U.S. and Europe, aiming for FDA pre-market approval and commercial launch by year-end 2023. The company also secured a €30 million strategic investment from Haemonetics as part of its Series D financing, with an option for acquisition upon milestone completion. The global market for large hole vessel closure is valued at over $300 million, with strong growth potential, emphasizing the significance of this partnership and study.
Orchestra BioMed Holdings (Nasdaq: OBIO) announced its participation in two significant healthcare conferences in March 2023. The company will present at Oppenheimer’s 33rd Annual Healthcare Conference on March 13 at 4:00 PM ET and at the Barclays Global Healthcare Conference on March 14 at 10:45 AM ET. Orchestra BioMed focuses on accelerating biomedical technologies, particularly its flagship products for treating hypertension and atherosclerotic artery disease. The company collaborates with industry leaders like Medtronic and Terumo Corporation to enhance commercialization efforts.
Orchestra BioMed Holdings (Nasdaq: OBIO) announced that data from its BackBeat Cardiac Neuromodulation Therapy™ and Virtue® Sirolimus AngioInfusion™ Balloon programs will be presented at the Cardiovascular Research Technologies (CRT) 2023 Meeting in Washington, DC, from February 25-28, 2023. Dr. Daniel Burkhoff will present on 'Cardiac Neuromodulation Therapy for Medically Refractory Hypertension' on February 26, while Dr. Dean Kereiakes will cover the 'Virtue® Sirolimus AngioInfusion Balloon (SAB) Overview' on the same day. These presentations highlight Orchestra BioMed’s commitment to advancing technologies aimed at treating significant health risks like hypertension and artery disease.
FAQ
What is the current stock price of Orchestra BioMed Holdings Ordinary Shares (OBIO)?
What is the market cap of Orchestra BioMed Holdings Ordinary Shares (OBIO)?
What does Orchestra BioMed Holdings, Inc. specialize in?
What are the flagship products of Orchestra BioMed?
What recent milestone has Orchestra BioMed achieved?
Who are Orchestra BioMed's strategic partners?
What is BackBeat CNT?
What is Virtue Sirolimus AngioInfusion Balloon (SAB)?
How does Orchestra BioMed's business model work?
Where can I find more information about Orchestra BioMed?
What is the focus of the BACKBEAT pivotal study?
What is hypertension and why is it significant?
